In March 2025, the company declared new programs for a direct-to-purchaser presenting of its Wegovy weight loss drug. The company recognized a brand new pharmacy, known as NovoCare, which might cost prospects $499 per month for access to the drug, less than fifty percent the cost of the drug as a result of other pharmaceutical distribution networks